All Stories

  1. Reduced risk of colorectal cancer with non-sulfasalazine 5-ASAs in ulcerative colitis and Crohn’s disease and anti-TNF therapy in ulcerative colitis: a systematic review and meta-analysis

    Article • Frontline Gastroenterology, December 2025, BMJ

    Ross Porter

  2. Real-world retrospective cohort study of inflammatory bowel disease colorectal cancer surveillance

    Article • Frontline Gastroenterology, July 2025, BMJ

    Ross Porter

  3. Clinical outcomes in frail elderly patients undergoing small-bowel capsule endoscopy

    Article • Frontline Gastroenterology, November 2024, BMJ

    Ross Porter

  4. An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma

    Article • ESMO Open, May 2024, Elsevier

    Ross Porter

  5. Prophylactic Versus Endoscopy-driven Treatment of Crohn’s Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study]

    Article • Journal of Crohn s and Colitis, January 2024, Oxford University Press (OUP)

    Ross Porter

  6. QuPath Algorithm Accurately Identifies MLH1-Deficient Inflammatory Bowel Disease-Associated Colorectal Cancers in a Tissue Microarray

    Article • Diagnostics, May 2023, MDPI AG

    Ross Porter

  7. Subcellular Epithelial HMGB1 Expression Is Associated with Colorectal Neoplastic Progression, Male Sex, Mismatch Repair Protein Expression, Lymph Node Positivity, and an ‘Immune Cold’ Phenotype Associated with Poor Survival

    Article • Cancers, March 2023, MDPI AG

    Ross Porter

  8. c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions

    Article • World Journal of Gastroenterology, April 2022, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Ross Porter

  9. Interleukin-27 Regulates the Function of the Gastrointestinal Epithelial Barrier in a Human Tissue-Derived Organoid Model

    Article • Biology, March 2022, MDPI AG

    Ross Porter

  10. Clonal Transitions and Phenotypic Evolution in Barrett’s Esophagus

    Article • Gastroenterology, December 2021, Elsevier

    Ross Porter

  11. Endoscopically placed venting gastrostomy can be a safe and effective palliative intervention in benign and malignant gastrointestinal obstruction

    Article • Frontline Gastroenterology, September 2021, BMJ

    Ross Porter

  12. Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines

    Article • Journal of Crohn s and Colitis, June 2021, Oxford University Press (OUP)

    Ross Porter

  13. Lessons from recent medical history: an obsolete anti-reflux device in an older patient with variable gastrointestinal symptoms

    Article • Age and Ageing, May 2021, Oxford University Press (OUP)

    Ross Porter

  14. Colonic epithelial cathelicidin ( LL ‐37) expression intensity is associated with progression of colorectal cancer and presence of CD8 + T cell infiltrate

    Article • The Journal of Pathology Clinical Research, May 2021, Wiley

    Ross Porter

  15. Immunofluorescence on FFPE tissue sections from inflamed and non-inflamed human gut v1 (protocols.io.bsqendte)

    Article • February 2021, ZappyLab, Inc.

    Ross Porter

  16. Current concepts in tumour-derived organoids

    Article • British Journal of Cancer, July 2020, Springer Science + Business Media

    Ross Porter

  17. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis

    Article • F1000Research, April 2020, Faculty of 1000, Ltd.

    Ross Porter, Dr Gwo-tzer Ho

  18. Novel biomarkers for risk stratification of Barrett’s oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype

    Article • British Journal of Cancer, December 2019, Springer Science + Business Media

    Ross Porter

  19. Endoscopic gastrostomy - safety and survival patterns

    Article • Frontline Gastroenterology, November 2019, BMJ

    Ross Porter, Emma Metcalfe

  20. Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

    Article • Inflammatory Bowel Diseases, July 2018, Oxford University Press (OUP)

    Ross Porter

  21. Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia

    Article • Leukemia, February 2018, Springer Science + Business Media

    Ross Porter

  22. CXCR2 inhibition suppresses acute and chronic pancreatic inflammation

    Article • The Journal of Pathology, June 2015, Wiley

    Ross Porter